ÓŵÂ88

ÈȵãËÑË÷
ÓŵÂ88¡¤(ÖйúÓÎ)ÓÐÏÞ¹«Ë¾¹ÙÍø ÓŵÂ88¡¤(ÖйúÓÎ)ÓÐÏÞ¹«Ë¾¹ÙÍø
ÐÂÎÅ×ÊѶ
ÓŵÂ88¡¤(ÖйúÓÎ)ÓÐÏÞ¹«Ë¾¹ÙÍø
2026-03-04
ÓŵÂ88 Immutailin? PVDFתӡĤÐÂÆ·ÉÏÊÐ
ÔÚµ°°×ÖÊÓëºËËá¼ì²â·ÖÎöÀûÓÃÖУ¬NC תӡĤ£¨ÏõËáÏËÎ¬ËØÄ¤£©ÓëPVDF ×ªÓ¡Ä¤£¨¾ÛÆ«¶þ·úÒÒϩĤ£©ÊÇÁ½ÏîÖ÷ÌâµÄ¹ÌÏàÖ§³Ö½éÖÊ ¡£ËüÃÇÆ¾½è¸÷×Ô¹ÖÒìµÄ»úÄÜÓÅÊÆ£¬¿í·ºÀûÓÃÓÚ¿ÆÑÐË÷ÇóÓëҽѧÕï¶ÏÁìÓò£¬Îª·ÖÆçµÄ³¢ÊÔÖ¸±ê¡­
²é¿´ÏêÇé
ÓŵÂ88¡¤(ÖйúÓÎ)ÓÐÏÞ¹«Ë¾¹ÙÍø
242026.03
ȨÍþÈÏÖ¤+ÖÕ¶ËÈϿɣ¡ÓŵÂ88MD500΢ÉúÎï¿ì¼ìÒÇ£¬ÓÃÊý¾ÝÖþÀÎÔìÒ©ºÏ¹æ·ÀÏß
½üÈÕ£¬Õã½­ÓŵÂ88·ÖÎöÒÇÆ÷ÓÐÏÞ¹«Ë¾×ÔÖ÷Ñз¢µÄMD500ÐÍ΢ÉúÎï¼±¾ç¼ì²â·ÖÎöÒÇ£¬²»½ö˳Àûͨ¹ýÕ㽭ʡʳƷҩƷ¼ìÑé×êÑÐÔº£¨ÒÔϼò³Æ¡°Ê¡Ò©¼ìÔº¡±£©´úÌæ²½ÖèѧȨÍþÑéÖ¤£¬¸ü½«Õâ·ÝÑé¡­
ÓŵÂ88¡¤(ÖйúÓÎ)ÓÐÏÞ¹«Ë¾¹ÙÍø
132026.03
dzÎö¡¶GB/T 18281Ò½ÁƱ£½¡²úÆ·Ãð¾ú ÉúÎïÅúʾÎï¡·µÄ±ä¶¯Óëµ÷Õû
¡¶GB/T 18281Ò½ÁƱ£½¡²úÆ·Ãð¾ú ÉúÎïÅúʾÎï¡·ÊÇÓйØÉúÎïÅúʾ¼ÁµÄͨÓÃÐÔºÍרÓÃÐÔ³ß¶È ¡£Ð°桶GB/T 18281-2024 Ò½ÁƱ£½¡²úÆ·Ãð¾ú ÉúÎïÅúʾÎϵÁг߶ÈÓÚ2024Äê11ÔÂ28ÈÕ¡­
ÓŵÂ88¡¤(ÖйúÓÎ)ÓÐÏÞ¹«Ë¾¹ÙÍø
242026.02
¿¥ÆôгÌ£¬ÂíÁ¦È«¿ª£¡ ÓŵÂ88ÉúÎï½ñÈÕ¿ª¹¤À²£¡
·Ü½øÕýÆäʱ£¬¿ª¹¤Æôг̣¡Å©ÀúÕýÔ³õ°ËÉÏÎ磬ÓŵÂ88ÉúÎïдº¿ª¹¤µäÀñÔÚ¸÷¸öÔ°ÇøÍ¬²½½øÐÐ ¡£Õû¸öÓŵÂ88ÈË´ø×ÅдºµÄ³¯Æø³Á·µ¸Úλ£¬Ñ¸¿ì´Ó¡°¼ÙÆÚģʽ¡±Çл»ÖÁ¡°¹¤×÷ģʽ¡±£¬ÒÔ»ðÈÈ¡­
ÓŵÂ88¡¤(ÖйúÓÎ)ÓÐÏÞ¹«Ë¾¹ÙÍø
112026.02
2025ÓŵÂ88Äê¶È·þÎñ»ã±¨¡ª¡ªÒÔ·þÎñÖ®¹â£¬ÕÕÁÁ¿Æ¼¼Ö®Â·
¡°ÒÔ¿Í»§ÎªÖÐÐÄ¡±ÊÇÓŵÂ88ÉúÎïµÄ·þÎñ×ÚÖ¼ÎÒÃÇÓÅ»¯Á÷³Ì¡¢´´Ð¹滮ÓÃÐж¯Ú¹ÊÍ·þÎñ¼ÛÖµÓÃרҵÓëζÅ×®µÃ¿Í»§ÐÅÀµÕâÒ»ÄêÀۼƷþÎñ16,000+¼Ò¿Í»§·þÎñ×ã¼£±é²¼10+¸ö¹ú¶È30+¸ö³ÇÊÐ&nb¡­
ÓŵÂ88¡¤(ÖйúÓÎ)ÓÐÏÞ¹«Ë¾¹ÙÍø
112026.02
?ÓŵÂ88¸ºÑ¹¸ôÀëÆ÷¼¼ÊõÔڸ߻îÐÔÔ­ÁÏÒ©³ö²úÖеÄÀûÓÃ
Ò»¡¢ÂÉÀý¶Ô¶¾ÐÔÒ©Æ·³ö²úµÄÓйػ®¶¨¡ñ WHO TRS-957 ANNEX 3 WHO good manufacturing practices for pharmaceutical products containing hazardous substance¡­
¡¾ÍøÕ¾µØÍ¼¡¿